Alkem Laboratories receives EIR from USFDA for Daman facility

The company received Establishment Inspection Report (EIR) for its manufacturing facility located at Amaliya, Daman. The stock spurted up by more than 8 per cent following this development.

The inspection was concluded between March 19 to 27, 2018. The drug regulator issued Form 483 with 13 observations. In response to the same, the company submitted a detailed corrective and preventive action (CAPA) plan. The inspection is now closed, said the company in a filing to the bourses.

Alkem Laboratories is a leading pharma company with international operations. The company develops, manufacture and sells pharmaceutical and neutraceutical products. The company has a portfolio of over 700 branded generic drugs and is a market leader in the Indian pharmaceutical formulations sector. Its specialization includes anti-invectives, gastro-intestinal pain and vitamins, minerals and other nutrients.

At 15:18 hours, the stock of Alkem Laboratories was quoting Rs. 2,061 per share, up by 9.49 per cent on Tuesday, when the benchmark BSE Sensex was at 36,848.01, up by 129.41 points or 0.35 per cent.